Berita Kesehatan
Improving systemic corticosteroid stewardship in asthma
Rabu, 09 Nov 2022 10:00:37

William W. Busse

European Respiratory Journal 2022 60: 2201440; DOI: 10.1183/13993003.01440-2022


The discovery of cortisone for inflammatory diseases was a Nobel Laureate achievement for Philip Hench, Edward Kendall and Tadeus Reichstein in 1950, and one that changed therapeutic options to regulate inflammation [1]. When Dr Hench at the Mayo Clinic administered cortisone to a patient with severe, crippling rheumatoid arthritis [1], she was pain-free, no longer wheelchair bound, and walking in four days! The apparently “miraculous” effects of cortisone were confirmed in rheumatoid arthritis and extended to other diseases, including status asthmaticus in 1956 [2, 3]. A new era in asthma management had begun. The development of major side-effects with prolonged use of systemic cortisone, however, raised concerns about its long-term safety. Consequently, strategies to minimise the inevitable side-effects from cortisone began then and remain a priority today for many asthma patients.

Tweetable abstract @ERSpublications

New evidence in this issue of the ERJ indicates that the previous duration and cumulative dose of oral corticosteroids influence the likelihood to achieve corticosteroid tapering after initiating IL-5/IL5R biologics for severe asthma


  • Conflict of interest: W.W. Busse reports consultation/advisory board work for Sanofi, Regeneron, GlaxoSmithKline, AstraZeneca, Genentech and Novartis.

  • Received July 18, 2022.
  • Accepted August 17, 2022.